About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNANCT00886301

Fatty Liver and Ectopic Fat in Overweight and Obese Patients

The aim of the study is to find new clinico-biological and medical imaging parameters associated with non alcoholic steatohepatitis in overweight and obese patients.

Lead sponsor: Centre Hospitalier Universitaire de Nice•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Centre Hospitalier Universitaire de Nice

Non invasive assessment of liver fibrosis and liver inflammation and steatosis is clinically relevant in patients exposed to non alcoholic fatty liver diseases. The aim of the study is to find new clinico-biological and medical imaging parameters associated with non alcoholic steatohepatitis in overweight and obese patients. Fatty liver and ectopic fat accumulation will be particularly assessed.

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•BMI between 25 and 40
•ALAT level superior to normal level even after 3 months of diet
•alcohol consumption \< 20 g/j for women and \< 30 g/j for men

Exclusion Criteria

•HIV, hepatitis B virus, hepatitis C virus positive
•known hemochromatosis
•glycemia \> 1.26 g/L or under anti-diabetic treatment

Related studies

Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis

NCT03587831 · NASH - Nonalcoholic Steatohepatitis

CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome

NCT05623150 · Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, and more

RECRUITINGPhase 3

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT06632444 · Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis

A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

NCT02815891 · Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis

Identification of Liver Fibrosis Biomarkers

NCT06819917 · Non-alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 13, 2023Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment56

Start dateMar 2010

Last updatedNov 13, 2023

Condition

Steatohepatitis

Locations shown

Hepatogastroenterology, Hôpital l'Archet, CHU de Nice

Nice

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 13, 2023Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions